par Bonnefoi, Herve;Piccart-Gebhart, Martine ;Bogaerts, Jan;Mauriac, Louis;Fumoleau, Pierre;Brain, Etienne;Petit, Thierry;Rouanet, Philippe;Jassem, Jacek;Blot, Emmanuel;Zaman, Khalil;Cufer, Tanja;Lortholary, Alain;Lidbrink, Elisabet;André, Sylvie;Litière, Saskia;Dal Lago, Lissandra ;Becette, Véronique;Cameron, David A;Bergh, Jonas;Iggo, Richard;EORTC 10994/BIG 1-00 Study Investigators,
Référence Lancet oncology, 12, 6, page (527-539)
Publication Publié, 2011-06
Référence Lancet oncology, 12, 6, page (527-539)
Publication Publié, 2011-06
Article révisé par les pairs
Résumé : | TP53 has a crucial role in the DNA damage response. We therefore tested the hypothesis that taxanes confer a greater advantage than do anthracyclines on breast cancers with mutated TP53 than in those with wild-type TP53. |